Sun pharma launches “Flu Guard” for Covid-19 treatment.
Srishti Shankar, INN/Delhi
Sun Pharma launched a much-needed relief into the lives of many when it announced- that they have come up with- “Flu guard”. They have been working closely with the central and state government in order to make the drug available to the masses across the country.“Flu guard”, originally known as ‘Favi piravir’ 200 mg, priced Rs. 35 per tablet can be given to people experiencing mild to moderate symptoms.
‘Favi piravir’ was developed by Japan’s Fujifilm Holdings Corp under the brand name ‘Avigan’ for treating influenza. Favipiravir is the only oral antiviral treatment approved in India for the potential treatment of patients with moderate Covid-19 disease, the pharma company said.
With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. Hence, with the new launch, people might expect to see some relief in the prevailing conundrum which the pandemic has embarked upon us lately.
Adding up to the aforementioned details and highlights, launching “flu guard” at an economical price will help reduce the financial burden on many.
Let’s try to understand more closely about the history of Sun Pharma.
Sun Pharma is one of the world’s largest speciality generic pharmaceutical company and India’s top pharmaceutical company.
Sun Pharma was established by Mr.Dilip Sanghvi, in Vapi Gujarat, in the year 1983. Cardiology products were introduced in the year 1987, followed by gastroenterology products in 1989. Today, it is one of the largest chronic prescriptions in India and a market leader in neurology, cardiology, nephrology and orthopaedics.
Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States. The US is the single largest market, accounting for about 50% turnover; in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 26 locations, including plants in the US, Canada, Brazil, Mexico and Israel.
Favipiravir and another antiviral treatment, remdesivir, have emerged as the most sought after medicines to treat COVID-19 in India, which had already approved the drugs as emergency treatments to fight the outbreak.
Other Indian drugmakers developing or selling favipiravir include Glenmark Pharmaceuticals, Cipla and Hetero Labs.